Gaithersburg, MD, United States of America

Christine Tkaczyk

This inventor holds 12 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: Medimmune Limited, Humabs Biomed Sa, Medlmmune Limited. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christine Tkaczyk. Retrieved from https://idiyas.com/inventor/christine-tkaczyk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 5.4

ph-index = 6

Forward Citations = 83(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2016-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11970527 - Antibody directed againstclumping factor A (ClfA) (2024-04-30),

2. 11578119 - Antibodies directed againstleukotoxins (2023-02-14),

3. 11447543 - [object Object] (2022-09-20),

4. 11168133 - Combinations of anti-antibodies (2021-11-09),

5. 11155606 - Antibody directed againstclumping factor a (ClfA) (2021-10-26),

6. 11059884 - Antibodies directed againstleukotoxins (2021-07-13),

7. 10759849 - Methods of treating-associated diseases (2020-09-01),

8. 10730934 - Antibodies tosurface determinants (2020-08-04),

9. 10457724 - Methods of treating-associated diseases (2019-10-29),

10. 9879070 - [object Object] (2018-01-30),

11. 9845348 - [object Object] (2017-12-19),

12. 9527905 - [object Object] (2016-12-27),

Title: Christine Tkaczyk: Innovator in Monoclonal Antibody Development

Introduction

Christine Tkaczyk is a prominent inventor based in Gaithersburg, MD (US), known for her significant contributions to the field of monoclonal antibodies. With a total of 12 patents to her name, she has made remarkable strides in developing innovative solutions for treating infections.

Latest Patents

Among her latest patents is an antibody directed against clumping factor A (ClfA). This patent discloses a monoclonal antibody that specifically binds to the ClfA protein, along with compositions that include this antibody. The methods outlined in this patent focus on treating infections by administering the anti-ClfA monoclonal antibody, either alone or in combination with another monoclonal antibody that targets alpha toxin (AT) protein. Additionally, she has developed bispecific monoclonal antibodies that bind to both ClfA and AT, providing new avenues for treatment. Another significant patent involves antibodies directed against leukotoxins, which can be utilized to detect leukotoxin and in methods for treating and preventing infections.

Career Highlights

Christine has worked with notable companies such as MedImmune Limited and Humabs Biomed SA, where she has honed her expertise in antibody development. Her work has been instrumental in advancing therapeutic options in the medical field.

Collaborations

Throughout her career, Christine has collaborated with talented individuals, including Bret Sellman and Lei Hua, contributing to a dynamic research environment that fosters innovation.

Conclusion

Christine Tkaczyk's work in monoclonal antibody development showcases her dedication to advancing medical science. Her innovative patents and collaborations highlight her significant impact in the field.

Profile summary based on public USPTO records.